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Cryptococcus neoformans is an encapsulated yeast causing mainly opportu-
nistic infections. DNA molecular typing techniques divided C. neoformans 
into four major molecular types (AFLP1/VNI, AFLP1A/VNB/VNII, AFLP1B/ 
VNII, AFLP3/VNIII, AFLP2/VNIV) characterized by different pathogenicity, 
geographical distribution and susceptibility to antifungal treatments. In this 
study 170 Italian C. neoformans clinical isolates (CI) and 32 environmental 
isolates (EI), collected and serotyped during a ten-year period (1985 to 1995), 
were genotyped using [GACA]4 microsatellite PCR fingerprinting. The mole-
cular types were compared to their geographic distribution, specimen sources 
and patient’s risk factors. All four molecular types were described among the 
CI and only VNI and VNIV among the EI. VNIV molecular type was isolated 
with significant prevalence among the CI and VNI among the EI. A different 
geographical distribution of molecular types was detected: VNIV was the most 
prevalent in the North and Center of Italy; VNIII was isolated almost exclu-
sively in the Center. No significant correlation among molecular types versus 
predisposing diseases or isolation sources was detected. The strains isolated 
from different body sites of the same patient (17 cases) were of the same ge-
notype. Five out 9 cases relapsed with a different molecular type. This prelim-
inary investigation shows a high intraspecies variability and reveals a non- 
homogeneous distribution of C. neoformans molecular types in Italy. 
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1. Introduction 
The genus Cryptococcus comprises more than 70 basidiomycetous fungal spe-
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cies characterized as variously encapsulated budding yeasts, of which mostly 
Cryptococcus neoformans and Cryptococcus gattii have been associated with 
life-threatening infections in humans and other animals, while infections with 
other species have rarely been reported [1]. Recently, a new taxonomic proposal 
splits C. neoformans into two species (C. neoformans and Cryptococcus deneo-
formans) and C. gattii into a total of five species (C. gattii, Cryptococcus bacil-
lisporus, Cryptococcus deuterogattii, Cryptococcus tetragattii and Cryptococcus 
decagattii) [2]. Since this is still under discussion [3], in this study we continue 
to adopt the classical taxonomy which classifies the agents of cryptococcosis into 
two species, C. neoformans and C. gattii. C. neoformans is classified into two va-
rieties and three serotypes: C. neoformans var. grubii (serotype A), C. neofor-
mans var. neoformans (serotype D) and the hybrid serotype AD, whereas C. gat-
tii comprises two serotypes, B and C [4]. 
Several molecular typing methods have been used for studying the molecular 
epidemiology of C. neoformans/C. gattii species complex. The most common 
approaches include amplified fragment length polymorphism (AFLP) analysis 
[5], PCR fingerprinting [6], PCR-restriction fragment length polymorphism 
(RFLP) analysis [7] as well as multi locus sequence typing (MLST) [8]. DNA mo-
lecular typing techniques divide C. neoformans into four major molecular types 
(AFLP1/VNI, AFLP1A/VNB/VNII, AFLP1B/VNII, AFLP3/VNIII, AFLP2/VNIV) 
characterized by different pathogenicity, geographical distribution and suscepti-
bility to antifungal treatments [9] [10]. C. neoformans var. grubii (serotype 
A/VNI genotype) has a worldwide distribution and is responsible for more than 
80% of cryptococcal diseases [11] [12], whereas C. neoformans var. neoformans 
(serotype D/VNIV genotype) is found predominantly in Western Europe [9] 
[13] and South America [12] [14]. In addition, in the Mediterranean area of Eu-
rope, a higher prevalence of C. neoformans serotype AD hybrids (VNIII geno-
type) has been reported [15] [16].  
In this study we investigated the genetic diversity of 202 clinical and environ-
mental C. neoformans isolates, collected during the 1985-1995 period. The clin-
ical strains were previously characterized [17] [18] but a comprehensive geno-
typic analysis of all collected C. neoformans strains has not been performed. For 
this purpose a preliminary genomic characterization, using the microsatellite 
PCR genotyping technique, was performed to assess the genetic diversity among 
Italian C. neoformans strains isolated in the early years of the AIDS outbreak. 
2. Materials and Methods 
One hundred and seventy Italian C. neoformans clinical isolates (CI) and 32 en-
vironmental isolates (EI), collected from 1985 to 1995 and stored in the Micro-
biology laboratory of Florence University, were typed by PCR fingerprinting. At 
the time of isolation, all the strains were identified by classical methods based on 
the urease production on Christensen’s Urea Agar, the presence of a capsule, the 
melanin production and the assimilation of nitrogen and carbon sources [19]. 
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To distinguish between C. neoformans and C. gattii, culture on canavanine-glycine- 
bromothymol blue (CGB) medium [20] and growth in the medium containing 
d-proline [21] have been performed. In addition, all strains identification were 
also performed using the ID32C system (BioMérieux AS, Marcy l’Etoile, France). 
Slide agglutination test with specific monoclonal antibodies for capsular poly-
saccharide Crypto-check kit (Iatron Laboratories Inc., Tokio, Japan) was used 
for serotyping. The human strains, 77 serotype A and 93 serotype D, were iso-
lated from 134 patients, hospitalized in 21 different cities, mainly in northern 
and central Italy. From seventeen patients, two or more specimens were col-
lected from different body sites. Nine patients had relapses of cryptococcal infec-
tions defined by a period between two positive cultures of more than 120 days. 
Pre-existing condition in patients were HIV/AIDS (n = 121, 90.3%), non-HIV/ 
AIDS-related immunodeficiency (n = 7, 5.2%) (e.g., immunosuppressive therapy 
or organ transplantation), immunocompetent (n = 2, 1.5%), and “unknown” for 
4 patients (2.9%). The CI were mainly from liquor (n=110, 65%), blood (n= 26, 
15%) and the 20% (n = 34) from other clinical specimens (i.e. urine, skin, spu-
tum, prostatic secretions). Environmental isolates were from soil (n = 14) and 
bird dried excreta (n = 18), mostly from pigeons, sampled in the north (n = 16), 
center (n = 2) and south (n = 14) of Italy. Twenty-two were serotype A and 10 
serotype D.  
Each isolate was stored at room temperature in sterile distilled water and an-
nually checked. Prior to the molecular biological analysis, the strains were re-
vived and checked for purity by sub culturing on Sabouraud dextrose agar (Difco- 
Becton, Dickinson and Company, Milan, Italy) at 37˚C for 7 days. 
The following set of laboratory standard reference strains, representing each 
of the eight major molecular types of the C. neoformans/C. gattii species com-
plex were used: WM148 (serotype A, VNI), WM626 (serotype A, VNII), WM628 
(serotype AD, VNIII), WM629 (serotype D, VNIV), WM179 (serotype B, VGI), 
WM178 (serotype B, VGII), WM161 (serotype B, VGIII), and WM779 (serotype 
C, VGIV) [6]. 
For this study, the strains were cultured on Sabouraud dextrose agar at 37˚C 
for 48 h and the phenol-chloroform DNA extraction was performed as pre-
viously described [22]. The microsatellite-specific primer [GACA]4 (5’ GAC 
AGACAGACAGACA 3’) was used as a single primer in the PCR reactions, car-
ried out in a final volume of 50 μl. Each reaction tube contained 1 × PCR buffer 
(10 mM Tri-HCl pH 8.3, 50 mM HCl, 1.5 mM MgCl2) (Applied Biosystems, 
Foster City CA, USA), 3 mM MgAcetate (Sigma Chemical Co. St. Louis, MO, 
USA), 200 µM each of dATP, dTTP, dCTP, dGTP (Boehringer, Mannheim, 
Germany), 2.5 U AmpliTaq DNA polymerase (Applied Biosystems, Foster City 
CA, USA), 160 ng primer [GACA]4, 25 ng DNA. PCR was performed for 35 
cycles: denaturation 94˚C for 20 second, annealing 50˚C for 1 minute, extension 
72˚C for 20 seconds, followed by a final extension cycle for 6 minutes at 72˚C 
[6]. All PCR reactions were carried out in a thermal cycler (2720 Applied Bio-
systems, Foster City CA, USA) and each isolate was amplified in duplicate. Am-
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plification products were electrophoresed on 1.4% agarose gel at 60 V for 14 cm. 
After a complete run, banding patterns were assigned visually by comparison 
with the molecular weight marker standard VI (Roche Diagnostics Germany). 
The molecular types were assigned by comparison to the standard molecular 
type strains [6] (Figure 1). Only unambiguous and reproducible bands were in-
cluded in the analysis.  
For the statistical analysis, percentages were compared using the chi-square or 
the Fisher’s exact test. A p-value of ≤0.05 was considered statistically significant. 
The possible correlation between the molecular types of the tested isolates versus 
predisposing disease or isolation sources was investigated using Pearson’s and 
Spearman’s correlation coefficient. 
3. Results 
All four molecular types were described among CI and only VNI and VNIV 
among EI. Overall serotype A belong to VNI molecular type (n = 69), VNII (n = 
2), VNIII (n = 20) and VNIV (n = 8). Serotype D is associated mostly with 
VNIV molecular type (n = 101) and very few isolates with VNIII (n = 1) and 
VNI (n = 1). VNIV molecular type was isolated with significant prevalence 
among CI (p < 0.01) and VNI among the EI (Table 1).  
The VNIV molecular type was the most prevalent in the North and Center of 
Italy (69% and 49% respectively). The VNIII molecular type was isolated mainly 
in the Center of Italy (20%) with a significant prevalence (p < 0.05) (Table 2). 
Both environmental and clinical strains isolated in Southern Italy were VNI 
genotype, except for one VNIV clinical isolate. 
Most of the isolates were from liquor of AIDS patients. From this group of pa-
tients all four molecular types have been described (Table 3). 
 
 
M: molecular weight marker standard, B: control without DNA, 1 - 2: VNI molecular type, 3 - 4: 
VNII molecular type, 5 - 6: VNIII molecular type, 7 - 8: VNIV molecular type  
Figure 1. Electrophoretic separation of PCR fingerprinting products obtained by ampli-
fying C. neoformans DNA with the single primer (GACA)4. 
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Table 1. Genotyping by (GACA)4 PCR fingerprinting of Cryptococcus neoformans clini-
cal and environmental isolates. 
Genotype 
Clinical isolates N (%) Environmental isolates N (%) 
Serotype A Serotype D Total Serotype A Serotype D Total 
VNI 47 1 48 (28%) 22 0 22 (69%)c 
VNII 2 0 2 (1%) 0 0 0 
VNIII 20 1 21 (12%) 0 0 0 
VNIV 8 91 99 (58%)a 0 10 10 (31%) 
Total 77 (45%) 93 (55%) 170 22 (69%)b 10 (31%) 32 
a. p < 0.01, b. p < 0.05, c. p < 0.01. 
 
Table 2. Geographic distribution of the Cryptococcus neoformans molecular types. 
Genotype 
Clinical isolates N (%) Environmental isolates N (%) 
North Center South North Center South 
VNI 23 (24%) 19 (28%) 6 (86%) 8 (50%) 0 14 (100%) 
VNII 0 2 (3%) 0 0 0 0 
VNIII 7 (7%) 14 (20%)a 0 0 0 0 
VNIV 65 (69%) 33 (49%) 1(14%) 8 (50%) 2 (100%) 0 
Total 95 68 7 16 2 14 
a. p < 0.05 
 
Table 3. Distribution of the molecular types according to the underlying disease and the specimen sources of the Clinical Isolates. 
Genotype 
Disease Specimen sources 
AIDS Other immunodeficiency No immunodeficiency Unknown status Liquor Blood Skin Outer sources 
Unknown 
sources 
VNI 37 6a 0 5 34 5 0 5 4 
VNII 1 1 0 0 1 0 1 0 0 
VNIII 20 1 0 0 15 4 0 2 0 
VNIV 93 2 2 2 60 17 7 14 1 
Total 151 10 2 7 110 26 8 21 5 
a. p < 0.05 
 
Among the isolates from patients with immunodeficiency other than AIDS, 
VNI was significantly prevalent (p < 0.05).  
The less represented VNII molecular type were isolated from a single liquor 
sample of a leukemic patient relapsed and from a skin specimen of an AIDS pa-
tient, both in the central Italy. 
The VNIII strains were isolated almost exclusively from patients with AIDS. 
The two isolates from immunocompetent patients showed VNIV molecular 
type.  
No significant correlation among the molecular types versus pre-existing con-
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ditions or isolation sources was detected. 
When specimens were obtained in a single patient from multiple body sites (n 
= 17), Cryptococcus isolates were from the same species and molecular type. In-
stead, the isolates collected during relapse presented a different molecular type 
from those from first infection in five cases out of nine. The shift more frequent 
was from VNIV to VNIII or conversely. 
4. Discussion 
Worldwide C. neoformans var. grubii, VNI, is the cause of more than 80% of all 
cryptococcal infections, mostly in immunocompromised patients [12]. In con-
trast, our results revealed that VNIV molecular type was the most prevalent spe-
cies causing infection (58%) in the population considered in this study, especial-
ly in AIDS patients. In addition, VNIV prevalence resulted higher than in others 
European and Italian reports (14% - 35%) [16] [23] [24] [25].  
Previous studies [26] reported a higher prevalence of C. neoformans. var. gru-
bii (VNI) in the south of Italy, while C. neoformans var. neoformans (VNIV) 
seems more common in the north [16] [24]. Our results support the same trend 
of data. Indeed, Cryptococcus molecular types were not homogeneously distri-
buted among Italy with a clear prevalence of VNIV in the north, while VNI pre-
vailed in the south, both among the CI that among the EI. This might reflect a 
different susceptibility to temperature [27]. The VNIII molecular type was found 
with a significantly higher percentage in central Italy than in the north (20 and 
7% respectively) and it was not found in the south. In the center of Italy the two 
haploid forms (VNI and VNIV) were found in similar percentages and this 
might have facilitated the emergence of hybrid strains. 
The only two isolates VNII genotype recovered in this study confirms the rare 
distribution in Italy [28] and worldwide [10] [12] [15].  
Classically serotype A is associated to VNI and VNII molecular type, and se-
rotype D to VNIV. Discrepancies between serotype and molecular type were 
observed in this study as 8 serotype A isolates were found belonging to VNIV 
molecular type and one serotype D was found belonging to VNI. This is possible 
due to the limit of serotyping method performed in the ‘90, compared with PCR 
fingerprinting, combined with the high presence of hybrids in Europe [16] [29] 
which can differently express serotype. In our investigation, most of the VNIII 
isolates were previously considered to be of serotype A (95%), probably because 
some hybrid forms of C. neoformans only show one serotype as reported in oth-
er studies [15] [24] [29].  
In this study VNI prevalence was significantly higher among non-HIV/AIDS 
patients compared to AIDS patients. Molecular type VNI is known to be an im-
portant agent of cryptococcal meningitis in both immunocompromised and 
immunocompetent patients in Italy [28]. In addition, these results are in agree-
ment with studies from Korea and Japan that identified a clonal population, 
designated genotype VNIc, commonly isolated from non-AIDS patients [30] 
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[31].  
All the isolates from the skin were VNIV molecular type, excluded one VNII 
isolate, both from immunocompetent and AIDS patients. This finding con-
firmed the association of serotype D/VNIV molecular type with cutaneous le-
sions reported in previous studies [24] [32]. The dermatotropism associated with 
serotype D/VNIV molecular type strains can be caused by the greater thermal 
susceptibility in infected tissues and it may reflect a preference of VNIV mole-
cular type for growth in the cooler tissues of the skin [27]. 
The reports of multiple infections caused by strains with different genotypes 
are increased [10] [33]. Desnoss-Olliver et al. [29] found in France a high pro-
portion (21.5%) of proven or probable infections due to a mixture of genotypes, 
serotypes and/or ploidies of C. neoformans strains. In our research, the strains 
isolates during Cryptococcus infections were characterized by a single molecular 
type, while the relapses were mostly caused by molecular types different from 
the ones described in the previous infection, suggesting a new acquired infec-
tion.  
The (GACA)4-PCR fingerprinting typing method provided interesting results 
but further genomic typing investigations, such as multi locus sequence typing 
technique, are needed to better understand the molecular epidemiology of cryp-
tococcosis in Italy in the early years of the AIDS outbreak. 
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